Skip to main content
. 2016 Sep 26;7(46):75441–75456. doi: 10.18632/oncotarget.12254

Figure 6. Targeted silencing of TACC3 suppresses CCA tumorigenicity and metastasis, in vivo.

Figure 6

A. The effects of TACC3 silencing on tumor suppression in vivo. Images of tumors formed in nude mice injected subcutaneously with HuCCT-1 cells transfected with the blank, negative vector, and TACC3 shRNA-1 (upper). Images of tumors formed in nude mice injected subcutaneously with TFK-1 cells transfected with the blank, negative vector and TACC3 shRNA-2 (lower). Tumor growth curves are plotted (right). **P<0.001. B. A pulmonary metastasis model was established after 6 weeks of the indicated treatment. Images from the pulmonary metastasis model (upper panel) and the corresponding statistical analysis (lower panel) are shown. *P<0.05 and **P<0.001. C. qRT-PCR (upper panel) and WB (middle and lower panel) were used to assess TACC3 mRNA and protein expression in tumor xenografts. *P<0.05. D. IHC was used to detect the expression of TACC3 in tumor xenografts and pulmonary metastasis tumor tissues (400X). Scale bar, 100 μm.